Loading...
Loading...
Contributors:
Dataset URI:
10.6084/m9.figshare.1279418.v1P-glycoprotein (P-gp, MDR1) is a promiscuous drug efflux pump of substantial pharmacological importance. Taking advantage of large-scale cytotoxicity screening data involving 60 cancer cell lines (NCI-60), we correlated the differential biological activities of ∼13 000 compounds against cellular P-gp levels. We created a large set of 934 high-confidence P-gp substrates or nonsubstrates by enforcing agreement with an orthogonal criterion involving P-gp overexpressing ADR-RES cells. A support vector machine (SVM) was 86.7% accurate in discriminating P-gp substrates on independent test data, exceeding previous models. Two molecular features had an overarching influence: nearly all P-gp substrates were large (>35 atoms including H) and dense (specific volume of Biological experiments on an independent P-gp overexpressing cell line, the vincristine-resistant VK2, allowed us to reclassify six compounds previously annotated as substrates, validating our method’s predictive ability. Models are freely available at pgp.biozyne.com. Legend: the column header "NSC" denotes a NCI compound ID number. Class "-1" is a P-gp nonsubstrate, and "1" is a substrate, according to the criteria described in our publication in J Med Chem, 2013, 56 (14). DOI: 10.1021/jm400328s
Keyword(s):
ABCB1; cancer cell lines; Cheminformatics; Cheminformatics and quantitative structure-activity relationships; drug efflux pumps.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
No Associated Publication Data Available
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)